A clinical‑stage biotechnology company focused on developing therapies for neurological disorders, with research programs targeting conditions such as hereditary ataxias and related rare diseases. The firm’s value is largely tied to clinical trial progress, intellectual property, and regulatory mile...
1 member of Congress has disclosed 1 trade in Ataxis PLC (ATXS), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2014-06-27 | DAVE CAMP | buy | $1K – $15K |